Saturday 17 October 2026
Export NNOX’s income statement to Excel — free account
Nano-X Imaging Ltd.
NNOX Healthcare Medical Devices
Nano-X Imaging Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $13.0 million, up 15.4% from fiscal 2024. In the quarter to June 2026, revenue grew 36.7%, EPS fell 243.5%, free cash flow fell 21.4% and total debt fell 12.0%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
0.45
0.04
−8.16%
Follow NNOX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
5.19 | 10.89 | 13.93 | 19.35 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.00) | (11.33) | (17.42) | (22.16) | |
P/B ratio |
1.12 | 1.25 | 1.30 | 1.52 | |
Price to Tangible BV |
1.40 | 2.30 | 2.28 | 2.51 | |
EV/Sales |
3.61 | 8.30 | 10.66 | 16.21 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.21) | (2.71) | (3.40) | (4.87) | |
EV/FCF |
(1.08) | (2.42) | (3.08) | (4.40) | |
Quick Ratio |
2.40 | 3.26 | 3.03 | 3.80 | |
Current Ratio |
2.84 | 3.64 | 3.96 | 4.14 | |
Net Debt/EBITDA |
0.53 | 3.48 | 1.41 | 3.74 | |
Debt/Assets |
3.20% | 2.04% | 1.93% | 1.82% | |
Debt/Equity |
0.04 | 0.02 | 0.02 | 0.02 | |
Asset Turnover |
0.11 | 0.08 | 0.07 | 0.07 | |
Operating CF/Net income |
0.21 | 0.98 | 0.31 | 0.78 | |
Capex/Depreciation |
(0.35) | (0.63) | (0.31) | (0.58) | |
Research and Development Expense of Revenue |
113.26% | 111.30% | 130.09% | 133.04% | |
Selling, General and Administrative Expense of Revenue |
176.71% | 171.75% | 216.32% | 196.23% | |
Intangible Assets out of Total Assets |
0.16 | 0.40 | 0.37 | 0.35 | |
Share Based Compensation of Revenue |
20.91% | 19.51% | 21.89% | 31.88% | |
Graham Net Nets |
0.25 | 0.20 | 0.24 | 0.13 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(146.78%) | (50.34%) | (41.17%) | (23.86%) | |
Free Cash Flow Yield |
(64.22%) | (31.56%) | (24.81%) | (19.02%) | |
Revenue per Share |
0.06 | 0.06 | 0.06 | 0.05 | |
Operating CF per Share |
(0.17) | (0.20) | (0.16) | (0.17) | |
Capex per Share |
(0.01) | (0.03) | (0.01) | (0.03) | |
Free Cash Flow per Share |
(0.18) | (0.23) | (0.17) | (0.19) | |
Cash per Share |
0.44 | 0.63 | 0.76 | 0.70 | |
Shareholders Equity per Share |
1.04 | 1.81 | 2.16 | 2.44 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.04 | 1.81 | 2.16 | 2.44 | |
Free Cash Flow |
(12.58) | (15.73) | (11.30) | (12.48) | |
Working Capital |
25.27 | 37.21 | 49.91 | 38.92 | |
Capital Expenditures |
(0.98) | (1.78) | (0.89) | (1.74) | |
Net Current Asset Value |
20.27 | 31.87 | 44.36 | 31.94 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.24 | 0.41 | 0.24 | 0.50 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.88 | 1.97 | 1.91 | 1.71 | |
Average Payables |
2.21 | 2.17 | 2.55 | 1.37 | |
Average Inventory |
2.83 | 2.51 | 2.28 | 1.85 | |
Average Assets |
137.71 | 171.25 | 186.08 | 180.01 | |
Average Common Equity |
118.01 | 151.74 | 164.43 | 160.30 |
Columns are period end dates